reform research tirzepatide Reduces Food Intake and Appetite, and Affects Brain Functioning, more than a Placebo and Liraglutide Tirzepatide from SSRBIO
Description
2021 Injectable semaglutide is approved in doses of up to 2.4mg/weekly under the brand name Wegovy as a weight loss therapy in adults with a BMI27 (and weight-related comorbidities) or BMI30 [6]

Clinical research also shows tirzepatide may improve testosterone levels in men beyond weight loss alone

These findings are consistent with indirect comparisons from network meta-analyses and systematic reviews, which generally report superior weight-loss outcomes with tirzepatide compared with GLP-1 receptor agonists alone

Hamza M, Papamargaritis D, Davies MJ

doi: 10.1016/j.envpol.2024.123332 100 TschuckJTheilackerLRothenaignerIWeissSAIAkdoganBLamVTet al
